- Home
- PRK vs DNLI Comparison
PRK vs DNLI Comparison
Compare PRK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRK
- DNLI
- Stock Information
- Founded
- PRK 1908
- DNLI 2013
- Country
- PRK United States
- DNLI United States
- Employees
- PRK N/A
- DNLI N/A
- Industry
- PRK Major Banks
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRK Finance
- DNLI Health Care
- Exchange
- PRK Nasdaq
- DNLI Nasdaq
- Market Cap
- PRK 2.5B
- DNLI 2.5B
- IPO Year
- PRK N/A
- DNLI 2017
- Fundamental
- Price
- PRK $153.33
- DNLI $18.78
- Analyst Decision
- PRK Hold
- DNLI Strong Buy
- Analyst Count
- PRK 3
- DNLI 13
- Target Price
- PRK $178.00
- DNLI $32.64
- AVG Volume (30 Days)
- PRK 61.8K
- DNLI 1.4M
- Earning Date
- PRK 10-27-2025
- DNLI 11-06-2025
- Dividend Yield
- PRK 2.78%
- DNLI N/A
- EPS Growth
- PRK 28.24
- DNLI N/A
- EPS
- PRK 10.85
- DNLI N/A
- Revenue
- PRK $535,826,000.00
- DNLI N/A
- Revenue This Year
- PRK $10.95
- DNLI N/A
- Revenue Next Year
- PRK $12.58
- DNLI $94,232.03
- P/E Ratio
- PRK $14.20
- DNLI N/A
- Revenue Growth
- PRK 10.64
- DNLI N/A
- 52 Week Low
- PRK $137.97
- DNLI $10.57
- 52 Week High
- PRK $207.99
- DNLI $26.18
- Technical
- Relative Strength Index (RSI)
- PRK 46.82
- DNLI 68.55
- Support Level
- PRK $149.55
- DNLI $16.85
- Resistance Level
- PRK $155.82
- DNLI $18.21
- Average True Range (ATR)
- PRK 3.85
- DNLI 1.14
- MACD
- PRK 0.17
- DNLI 0.19
- Stochastic Oscillator
- PRK 38.66
- DNLI 99.71
About PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.